ArticleAddiction biology2026
Corticosteroid Receptor Modulation in the Dorsal Striatum Prevents Morphine-Induced Place Preference and Reduction in Dopamine Transporter (DAT) Immunoreactivity in Rats.
Article in Addiction biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Stress hormones and corticosteroid signalling influence dopaminergic transmission and reward-related behaviours. The present study investigated whether pharmacological manipulation of corticosteroid signalling within the dorsal striatum influences morphine-induced conditioned place preference (CPP) and dopamine transporter (DAT) regulation. Male Wistar rats were implanted with bilateral intra-dorsal striatal cannulae and subjected to the CPP paradigm. Before conditioning sessions, animals received bilateral intra-dorsal striatal infusions of corticosterone, the glucocorticoid receptor (GR) antagonist RU-38486 or the mineralocorticoid receptor (MR) antagonist spironolactone. Behavioural preference, locomotor activity and DAT immunoreactivity were subsequently assessed. Morphine reliably induced CPP and reduced DAT immunoreactivity in the dorsal striatum. Corticosterone, RU-38486 and spironolactone each significantly attenuated morphine-induced CPP and prevented the reduction in DAT immunoreactivity without altering locomotor activity. The convergence of these pharmacologically distinct manipulations on similar behavioural and DAT outcomes suggests that perturbation of corticosteroid-sensitive signalling within the dorsal striatum modulates opioid reward and associated dopaminergic plasticity. Importantly, the present findings do not establish whether corticosterone's effect is mediated by classical GR signalling, rapid corticosteroid actions or GR-independent mechanisms. Given the role of the dorsal striatum in addiction-related learning and the transition towards habitual and compulsive drug seeking, these findings identify corticosteroid-dopamine interactions within this region as an important mechanism for further investigation in opioid use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.